Formulary Group work programme


Forthcoming submissions 2014

This list is indicative and may be subject to change.

Adalimumab - SMC 881/13 -  Formulary Group advice will be published by 2nd September 2014. (Indication: in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs)).

Alemtuzumab - SMC 959/14 - Formulary Group advice will be published by 2nd September 2014. (Indication: for adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features).

Aripiprazole - SMC 891/13- Formulary Group advice will be published by 2nd September 2014. (This SMC advice relates to an extension of the marketing authorisation for treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older).

Aripiprazole - SMC 962/14Formulary Group advice will be published by 2nd September 2014. (Indication: maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole).

Atomoxetine - SMC 909/13 - in progress. (Indication: treatment of attention-deficit/hyperactivity disorder (ADHD) in adults as part of a comprehensive treatment programme).

Budesonide - SMC 970/14 Formulary Group advice will be published by 2nd September 2014. (Indication: induction of remission in patients with mild to moderate active Crohns disease affecting the ileum and/or ascending colon).

Certolizumab  pegol - SMC 973/14 - in progress. (Indication: in combination with methotrexate, for the treatment of active psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug (DMARD) therapy has been inadequate).

Chlorhexidine - FG1358/14 - Formulary Group advice will be published by 2nd September 2014. (Indication: treatment of acanthaemoeba keratitis).

Dapagliflozin plus metformin (Xigduo®) - SMC 983/14 - Formulary Group advice will be published by 2nd September 2014. (Indication: in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control).

Eltrombopag - SMC 919/13 - in progress. (Indication: in adult patients with chronic hepatitis C virus infection, for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy).

Fesoterodine - FG1354/14 - in progress. (Indication: bladder overactivity).

Nalmefene - SMC 917/13 - in progress. (Indication: for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms, and who do not require immediate detoxification).

Nepafenac - SMC 813/12 - in progress. (Indication: reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients).

Ondanestron - SMC 912/13 - in progress. (Indication: in adults: Prophylaxis and treatment of acute and delayed nausea and vomiting induced by chemotherapy, and radiotherapy. Prophylaxis and treatment of post-operative nausea and vomiting.
In paediatric populations:Management of chemotherapy-induced nausea and vomiting in children aged ≥6 months and prophylaxis and treatment of post-operative nausea and vomiting (PONV) in children aged ≥4 years).

Ocriplasmin - SMC 892/13 - in progress. (Indication: in adults for the treatment of vitreomacular traction).

Rituximab subcutaneous injection - SMC 975/14 -  in progress. (Indication: for non-Hodgkin's lymphoma (NHL) in adults).

Tocilizumab - SMC 982/14 - in progress. (Indication: in combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients).

Ustekinumab - SMC 944/14 - in progress. (Indication: alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients).

Publication schedule

This web page is updated monthly, within 7 working days of publication of SMC advice.

END

« Previous: Formulary Group | Top | Next: Formulary Group decisions index »